36E79723R0018 0001.docx
DOCX document 34 KB Posted
- Attached to
- 6505--Ranibizumab Federal contract opportunity
- Solicitation number
- 36E79723R0018
About this file
This document is an amendment to a federal solicitation for ranibizumab ophthalmic injections. The amendment corrects estimated usage totals for Group I line items 1 and 2 and Group II line items 1 through 3. Usage totals for Group I items 1 and 2 are now 1,287 each. Usage totals for Group II items 1 through 3 are now 5,732 each. The response due date is extended to July 24, 2023 at 2:30 PM Central Time. Offerors must provide pricing for the base year and four option years for any items offered in Group I or II. The Department of Veterans Affairs National Acquisition Center is the contracting agency. The amendment requests pricing and drug information for ranibizumab ophthalmic injections to be considered for award under solicitation number 36E79723R0018.
View the file
Other files for this federal contract opportunity
| File | Type | Posted |
|---|---|---|
| 36E79723R0018.docx | DOCX document |
On GovTribe
Work with this file on GovTribe
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
5. PROJECT NUMBER (if applicable)
CODE
7.
ADMINISTERED BY
2. AMENDMENT/MODIFICATION NUMBER
CODE
6. ISSUED BY
8. NAME AND ADDRESS OF CONTRACTOR
4. REQUISITION/PURCHASE REQ. NUMBER
3. EFFECTIVE DATE
9A. AMENDMENT OF SOLICITATION NUMBER
9B. DATED
PAGE OF
PAGES
10A. MODIFICATION OF CONTRACT/ORDER NUMBER
10B. DATED
BPA NO.
1. CONTRACT ID CODE
FACILITY CODE
CODE
Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods:
The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers
E. IMPORTANT:
is extended,
(a) By completing Items 8 and 15, and returning __________ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE
OF YOUR
ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY is not extended.
12. ACCOUNTING AND APPROPRIATION DATA
(REV. 11/2016)
is required to sign this document and return ___________ copies to the issuing office.
is not, A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.
15C. DATE SIGNED
B. THE ABOVE NUMBERE
D CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES
SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).
RESULT IN REJECTION OF YOUR
OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by letter or electronic communication, provided each letter or electronic communication makes reference to the solicitation and this amendmen t, and is received prior to the opening hour and date specified.
C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
D. OTHER
Contractor
16C. DATE SIGNED
14. DESCRIPTION OF AMENDMENT/MODIFICATION
16B. UNITED
STATES OF AMERICA
Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.
15A. NAME AND TITLE OF SIGNER
16A. NAME AND TITLE OF
CONTRACTING OFFICER
15B. CONTRACTOR/OFFEROR
STANDARD FORM 30
PREVIOUS EDITION NOT USABLE
Prescribed by GSA - FAR (48 CFR) 53.243 (Type or print) (Type or print) (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
(Number, street, county, State and ZIP Code) (If other than Item 6) (Specify type of modification and authority) (such as changes in paying office, appropriation date, etc.)
(If required)
(SEE ITEM 11)
(SEE ITEM 13)
(X)
CHECK
ONE
13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS,
IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF
SOLICITATIONS
AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT
(Signature of person authorized to sign) (Signature of Contracting Officer) None Department of Veterans Affairs
OPAL /
National Acquisition Center Building 37 1st Avenue, One Block North of Cermak Hines IL 60141 Department of Veterans Affairs OPAL / National Acquisition Center Building 37 1st Avenue, One Block North of Cermak Hines IL 60141 To all Offerors/Bidders
36E79723R0018 07-06-2023
X X X
7/24/2023, 2:30PM CT
X One Correcting estimated usage totals and extending the response due date.
This amendment is issued to correct the estimated usage totals for both Groups I and II, and to extend the offer due date for solicitation 36E79723R0018 for Ranibizumab. The due date and time have been extended to July 24, 2023, 2:30PM Central Time.
See pages 2 - 4 for the corrected totals and pages from the solicitation. Offerors shall enter their proposed prices, NDCs, and BLA approval information on pages 2 and 3 of this amendment.
All other terms and conditions of this solicitation remain unchanged.
Nicholas I. McGregor Contracting Officer
Continuation of SF-1449, Block 3:
The following information shall be entered by the Contracting Officer at the time of contract award according to the timeframes specified in this solicitation’s Section B, Scope of Contract, Section 1.4 Contract Effective Date, Implementation Period, and Ordering Period.
Contract Award/Effective Date: ___________________
Implementation Period: __________________________
Ordering Period (Base Year): _____________________
Offerors shall not enter information into the above fields.
Continuation of SF-1449, Blocks 19 through 24:
To be considered for award, offerors must propose prices for the base and each option year for the proposed item within a product group or groups. Offerors are not required to submit an offer for both groups; however, the offeror must meet all contract requirements for each item offered. One award will be made for each Group - Group I and Group II - for the base years and all four option years. If a single offeror is awarded both groups, a single contract award including both line items/groups will be issued. Offered prices shall not exceed two decimal places.
Note: NDC is defined as National Drug Code. BLA is defined as Biologics License Application.
GROUP I
Line Item 1 Ranibizumab-EQRN 0.3/0.05ML INJ, OPTH (Ophthalmic) Trade Name – Cimerli 0.3MG/0.05ML INJ, OPTH Vial
NDC # __________________
BLA# _________________
Base Year
1,287
Vials
| $ |
| $ |
Option Year One
1,287
Vials
| $ |
| $ |
Option Year Two
1,287
Vials
| $ |
| $ |
Option Year Three
1,287
Vials
| $ |
| $ |
Option Year Four
1,287
Vials
| $ |
| $ |
OR OR OR OR OR
Line Item 2
RANIBIZUMAB 0.3MG/0.05ML INJ,OPTH,SYRINGE
Trade Name – Lucentis 0.3MG/0.05ML INJ, OPTH Syringe
NDC # __________________
BLA# _________________
Base Year
1,287
Syringes
| $ |
| $ |
Option Year One
1,287
Syringes
| $ |
| $ |
Option Year Two
1,287
Syringes
| $ |
| $ |
Option Year Three
1,287
Syringes
| $ |
| $ |
Option Year Four
1,287
Syringes
| $ |
| $ |
GROUP II
Line Item 1 Ranibizumab-EQRN 0.5/0.05ML INJ, OPTH Trade Name – Cimerli 0.5MG/0.05ML INJ, OPTH Vial
NDC # __________________
BLA# _________________
Base Year
5,732
Vials
| $ |
| $ |
Option Year One
5,732
Vials
| $ |
| $ |
Option Year Two
5,732
Vials
| $ |
| $ |
Option Year Three
5,732
Vials
| $ |
| $ |
Option Year Four
5,732
Vials
| $ |
| $ |
OR OR OR OR OR
Line Item 2 Ranibizumab 0.5MG/0.05ML INJ, OPTH Trade Name – Lucentis 0.5MG/0.05ML INJ, OPTH SYR
NDC # __________________
BLA# _________________
Base Year
5,732
Syringes
| $ |
| $ |
Option Year One
5,732
Syringes
| $ |
| $ |
Option Year Two
5,732
Syringes
| $ |
| $ |
Option Year Three
5,732
Syringes
| $ |
| $ |
Option Year Four
5,732
Syringes
| $ |
| $ |
OR OR OR OR OR
Line Item 3 Ranibizumab-NUNA 0.5MG/0.05ML INJ, OPTH Trade Name – Byooviz 0.5MG/0.05ML INJ, OPTH Vial
NDC # __________________
BLA# _________________
Base Year
5,732
Vials
| $ |
| $ |
Option Year One
5,732
Vials
| $ |
| $ |
Option Year Two
5,732
Vials
| $ |
| $ |
Option Year Three
5,732
Vials
| $ |
| $ |
Option Year Four
5,732
Vials
| $ |
| $ |
D.2 ATTACHMENT “B”
GROUP I RANIBIZUMAB 0.3MG/0.05ML INJ,OPTH
| ITEM |
| DESCRIPTION |
| TRADE NAME |
| VA EST ANNUAL USAGE |
| BOP EST ANNUAL USAGE |
| IHS EST ANNUAL USAGE |
| TOTAL EST USAGE |
| ITEM 1 |
| RANIBIZUMAB-EQRN 0.3MG/0.05ML INJ,OPTH |
| CIMERLI 0.3MG/0.05ML INJ,OPTH VIAL |
| 1,285 |
| 1 |
| 1 |
| 1,287 |
| OR |
| OR |
| OR |
| OR |
| OR |
| OR |
| OR |
| ITEM 2 |
| RANIBIZUMAB 0.3MG/0.05ML INJ,OPTH,SYRINGE |
| LUCENTIS 0.3MG/0.05ML INJ, OPTH SYRINGE |
| 1,285 |
| 1 |
| 1 |
| 1,287 |
GROUP II RANIBIZUMAB 0.5MG/0.05ML INJ,OPTH
| ITEM |
| DESCRIPTION |
| TRADE NAME |
| VA EST ANNUAL USAGE |
| BOP EST ANNUAL USAGE |
| IHS EST ANNUAL USAGE |
| TOTAL EST USAGE |
| ITEM 1 |
| RANIBIZUMAB-EQRN 0.5MG/0.05ML INJ,OPTH |
| CIMERLI 0.5MG/0.05ML INJ,OPTH VIAL |
| 5,730 |
| 1 |
| 1 |
| 5,732 |
| OR |
| OR |
| OR |
| OR |
| OR |
| OR |
| OR |
| ITEM 2 |
| RANIBIZUMAB 0.5MG/0.05ML INJ,OPTH |
| LUCENTIS 0.5MG/0.05ML INJ,OPTH SYR |
| 5,730 |
| 1 |
| 1 |
| 5,732 |
| OR |
| OR |
| OR |
| OR |
| OR |
| OR |
| OR |
| ITEM 3 |
| RANIBIZUMAB-NUNA 0.5MG/0.05ML INJ,OPTH |
| BYOOVIZ 0.5MG/0.05ML INJ,OPTH VIAL |
| 5,730 |
| 1 |
| 1 |
| 5,732 |
File details come from the government source that posted it. Updated .